Aurinia Pharmaceuticals Inc.
NASDAQ:AUPHBiotechnology
+$0.13 today
- Market cap
- $2.03B
- Beta
- 1.43
- P/E (TTM)
- 7.2
- EPS (TTM)
- $2.25
Volume 0.76M
Average 1.21M
AUPH Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Aurinia Pharmaceuticals Inc.NASDAQ: AUPH
Accounts Payables · Q2 FY2026 · quarter ended Jun 2026
Accounts payables growth accelerates
Q2 FY2026 accounts payables of $2.78M (cash outflow) rose 208.9% year over year, ahead of the -33.5% change in trailing-twelve-month accounts payables. Sequentially, it rose 326.8% from the prior quarter. Over 3 fiscal years it compounded at +33.3% a year.
Context
- Accounts payables amounted to 0.7% of revenue in FY2025, up 0.3 pp from a year earlier.
- Accounts payables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +208.9% holds above the trailing-twelve-month pace of -33.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (1.87M) USD
- Year-over-year change
- -317.9%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.87M) | -317.9% |
| FY2024 | 2024-12-31 | 860K | -30.6% |
| FY2023 | 2023-12-31 | 1.24M | +256.6% |
| FY2022 | 2022-12-31 | (792K) | -119.4% |
| FY2021 | 2021-12-31 | 4.08M | — |
Accounts Payables vs competitors
How AUPH compares with its peers on the latest reported figures
- AUPH's LTM Jun 2026 accounts payables of $3.39M is the 5th largest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of -33.5% is the 4th highest of 8, against a peer median of -86.9%.
- Accounts payables amounts to 1.1% of revenue for AUPH, versus a peer median of 34.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $8.3M | +286.2% | +184.2% | 99.2% | |
| LTM Jun 2026 | $7.51M | -417.2% | — | — | |
| LTM Mar 2026 | $4.83M | -1.4% | +47.8% | — | |
EVMNEvommune, Inc. | LTM Mar 2026 | $3.9M | — | — | 39.0% |
| LTM Jun 2026 | $3.39M | -33.5% | +33.3% | 1.1% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $2.18M | +391.0% | — | 29.5% |
| LTM Jun 2026 | $1.12M | -86.9% | +9.5% | — | |
| FY2025 | $180K | -89.5% | — | 13.3% | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $0 | -100.0% | — | — |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding AUPH) | $0 | -86.9% | +47.8% | 34.2% | |
Competitors are the stored peer set for AUPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (180.97M) | (108.18M) | (78.02M) | 5.75M | 287.2M |
| Depreciation & Amortization | 2.76M | 2.71M | 11.65M | 19.45M | 9.27M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | (176.19M) |
| Stock-Based Compensation | 31.24M | 32.3M | 45.31M | 31.6M | 14.68M |
| Change in Working Capital | (21.63M) | (6.82M) | (5.61M) | 5.45M | (8.78M) |
| Accounts Receivables | (15.42M) | 1.93M | (10.61M) | (12.46M) | (4.91M) |
| Inventory | (5.64M) | (9.07M) | (15.87M) | 477K | (6.46M) |
| Accounts Payables | 4.08M | (792K) | 1.24M | 860K | (1.87M) |
| Other Working Capital | (4.65M) | 1.12M | 19.63M | 16.57M | 4.46M |
| Other Non-Cash Items | 10.9M | 462K | (6.79M) | (17.85M) | 9.49M |
| Operating Cash Flow | (157.69M) | (79.53M) | (33.46M) | 44.39M | 135.66M |
| Capital Expenditures | (1.5M) | (292K) | (718K) | (281K) | (252K) |
| Acquisitions (Net) | (1.2M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (438.96M) | (523.99M) | (523.5M) | (545.83M) | (526.65M) |
| Sales of Investments | 354.43M | 464.32M | 529.38M | 585.42M | 494.13M |
| Other Investing Activities | (16.63M) | (663K) | (11.86M) | (43K) | 0 |
| Investing Cash Flow | (103.87M) | (60.63M) | (6.71M) | 39.26M | (32.77M) |
| Debt Repayment | 0 | 0 | (10.03M) | (11.99M) | (13.14M) |
| Common Stock Issued | 196.74M | 0 | 0 | 0 | 14.95M |
| Common Stock Repurchased | 0 | 0 | 0 | (40.24M) | (98.16M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 24.37M | 2.43M | 4.9M | 3.14M | (9.76M) |
| Financing Cash Flow | 221.11M | 2.43M | (5.13M) | (49.09M) | (106.11M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (40.45M) | (137.73M) | (45.3M) | 34.56M | (3.22M) |
| Free Cash Flow | (159.19M) | (79.82M) | (34.18M) | 44.11M | 135.41M |
Aurinia Pharmaceuticals Inc.
NASDAQ:AUPH
Intrinsic Alpha fair value
Locked
Current Price
$15.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.